company background image
4521 logo

Kaken Pharmaceutical TSE:4521 Stock Report

Last Price

JP¥3.73k

Market Cap

JP¥143.5b

7D

-2.9%

1Y

3.7%

Updated

13 Jun, 2024

Data

Company Financials +

Kaken Pharmaceutical Co., Ltd.

TSE:4521 Stock Report

Market Cap: JP¥143.5b

Kaken Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kaken Pharmaceutical
Historical stock prices
Current Share PriceJP¥3,733.00
52 Week HighJP¥3,985.00
52 Week LowJP¥3,161.00
Beta0.27
1 Month Change7.18%
3 Month Change5.93%
1 Year Change3.67%
3 Year Change-22.15%
5 Year Change-29.30%
Change since IPO55.54%

Recent News & Updates

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Mar 04
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Recent updates

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Mar 04
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Shareholder Returns

4521JP PharmaceuticalsJP Market
7D-2.9%-0.7%0.3%
1Y3.7%-0.7%17.5%

Return vs Industry: 4521 exceeded the JP Pharmaceuticals industry which returned -0.7% over the past year.

Return vs Market: 4521 underperformed the JP Market which returned 17.5% over the past year.

Price Volatility

Is 4521's price volatile compared to industry and market?
4521 volatility
4521 Average Weekly Movement3.3%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement3.9%
10% most volatile stocks in JP Market7.5%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4521 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4521's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19171,130Hiroyuki Horiuchiwww.kaken.co.jp

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens.

Kaken Pharmaceutical Co., Ltd. Fundamentals Summary

How do Kaken Pharmaceutical's earnings and revenue compare to its market cap?
4521 fundamental statistics
Market capJP¥143.53b
Earnings (TTM)JP¥8.03b
Revenue (TTM)JP¥72.04b

17.6x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4521 income statement (TTM)
RevenueJP¥72.04b
Cost of RevenueJP¥33.51b
Gross ProfitJP¥38.54b
Other ExpensesJP¥30.51b
EarningsJP¥8.03b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)211.91
Gross Margin53.49%
Net Profit Margin11.14%
Debt/Equity Ratio2.7%

How did 4521 perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

71%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.